

Rosario Pivonello

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/7004413/publications.pdf](https://exaly.com/author-pdf/7004413/publications.pdf)

Version: 2025-02-01

192

PR articles

11,042

PR citations

14970

57

PR h-index

22652

100

g-index

212

documents

12950

doc citations

13289

64

h-index

10379

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Exploring sexual function in adrenal insufficiency: findings from the Dual Release hydrocortisone versus conventional glucocorticoid replacement therapy in hypocortisolism (DREAM) trial. <i>Andrology</i> , 2025, 13, 302-313.	3.3	6
2	Long-term penile prosthesis couple's satisfaction: A systematic review and meta-analysis. <i>Andrology</i> , 2025, 13, 610-623.	3.3	5
3	Does an increase in adipose tissue "weight" affect male fertility? A systematic review and meta-analysis based on semen analysis performed using the WHO 2010 criteria. <i>Andrology</i> , 2024, 12, 123-136.	3.3	44
4	Effect of antioxidants on semen parameters in men with oligoasthenoteratozoospermia: a network meta-analysis. <i>Andrology</i> , 2024, 12, 538-552.	3.3	11
5	Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center. <i>Journal of Endocrinological Investigation</i> , 2024, 47, 1887-1901.	3.0	7
6	Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2024, 25, 707-725.	7.1	4
7	Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 2024, 47, 2437-2448.	3.0	9
8	Risk Assessment of Diabetes Mellitus During and After Pregnancy in Women With Prolactinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2024, 109, 3245-3253.	4.2	4
9	Cardiac magnetic resonance reveals biventricular impairment in Cushing's syndrome: a multicentre case-control study. <i>Endocrine</i> , 2024, 85, 937-946.	2.6	2
10	The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study. <i>Pituitary</i> , 2024, 27, 416-427.	2.8	15
11	Rapid Resolution of Recalcitrant Headache With Pasireotide in an Adult Patient With Acromegaly. , 2024, 2, .		2
12	1,25-Dihydroxyvitamin D3 mitigates the adipogenesis induced by bisphenol A in 3T3-L1 and hAMSC through miR-27-3p regulation. <i>International Journal of Obesity</i> , 2024, 48, 1793-1802.	3.2	6
13	Evaluating the Impact of Continuous Glucose Monitoring on Erectile Dysfunction in Type 1 Diabetes: A Focus on Reducing Glucose Variability and Inflammation. <i>Healthcare (Switzerland)</i> , 2024, 12, 1823.	2.3	1
14	Dietary Habits, Physical Activity and Body Mass Index in Transgender and Gender Diverse Adults in Italy: A Voluntary Sampling Observational Study. <i>Nutrients</i> , 2024, 16, 3139.	4.7	6
15	Fertility in Acromegaly: A Single-Center Experience of Female Patients During Active Disease and After Disease Remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, e583-e593.	4.2	9
16	Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1658.	2.6	4
17	Approach to the Patient With Prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2400-2423.	4.2	75
18	Unmet needs on the current medical management of Cushing's syndrome: results from a Delphi panel of Italian endocrinologists. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 1923-1934.	3.0	8

#	ARTICLE	IF	PR CITATIONS
19	Psychopathology in Acromegaly: Real and Perceived. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2470-2474.	4.2	7
20	Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. <i>Nature Reviews Endocrinology</i> , 2023, 19, 722-740.	36.0	264
21	The environment and male reproductive system: the potential role and underlying mechanisms of cadmium in testis cancer. <i>Critical Reviews in Toxicology</i> , 2023, 53, 412-435.	3.6	4
22	Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2023, 47, 655-669.	3.0	6
23	Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. <i>Frontiers in Endocrinology</i> , 2022, 12, .	4.1	16
24	Interferenti endocrini e funzione gonadica: focus su steroidogenesi testicolare e infertilità maschile. <i>L Endocrinologo</i> , 2022, 23, 52-60.	0.0	1
25	Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 941-961.	3.0	13
26	Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity. <i>Scientific Reports</i> , 2022, 12, .	3.5	12
27	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. <i>Obesity Reviews</i> , 2022, 23, .	7.9	34
28	The dopaminergic control of Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1297-1315.	3.0	17
29	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	2.7	6
30	Andrological effects of SARS-Cov-2 infection: a systematic review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 2207-2219.	3.0	52
31	MicroRNAs and Long Non-Coding RNAs in Adrenocortical Carcinoma. <i>Cells</i> , 2022, 11, 2234.	4.8	8
32	Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study. <i>Journal of Endocrinological Investigation</i> , 2022, 46, 181-188.	3.0	10
33	Testis-Specific Genes Deregulation in the Testis of COVID-19 Patients: A Potential Driver of Spermatogenesis Disruption?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	4.2	1
34	Etiology, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome. <i>Endocrine Practice</i> , 2021, 27, 471-477.	3.5	7
35	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 275-296.	7.1	188
36	Sperm Global DNA Methylation (SGDM) in Semen of Healthy Dogs. <i>Veterinary Sciences</i> , 2021, 8, 50.	2.0	3

#	ARTICLE	IF	PR CITATIONS
37	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, .	4.1	23
38	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2845-2847.	3.0	29
39	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 159-174.	3.1	14
40	Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, .	4.1	61
41	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. <i>Endocrine Practice</i> , 2021, 27, 1216-1224.	3.5	22
42	Hyperprolactinemia after menopause: Diagnosis and management. <i>Maturitas</i> , 2021, 151, 36-40.	3.1	15
43	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	22.6	736
44	Subclinical male hypogonadism. <i>Minerva Endocrinology</i> , 2021, 46, .	1.2	10
45	A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. <i>Frontiers in Endocrinology</i> , 2021, 12, .	4.1	23
46	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 22, 703-714.	7.1	44
47	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, .	4.1	114
48	Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 748-761.	22.6	185
49	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.3	3
50	Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1613-1622.	3.0	24
51	Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells. <i>Nutrients</i> , 2020, 12, 1798.	4.7	119
52	Bisphenol A: an emerging threat to female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, .	4.3	226
53	Erectile dysfunction and cardiovascular risk: a review of current findings. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 155-164.	1.9	58
54	Smoke, alcohol and drug addiction and female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, .	4.3	141

#	ARTICLE	IF	PR CITATIONS
55	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	4.0	37
56	Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, .	3.2	17
57	People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1391-1408.	3.0	53
58	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <i>Pituitary</i> , 2020, 24, 104-115.	2.8	23
59	ACTH increment post total bilateral adrenalectomy for Cushing's disease: a consistent biosignature for predicting Nelson's syndrome. <i>Pituitary</i> , 2020, 23, 488-497.	2.8	16
60	Advances in the medical treatment of Cushing's syndrome. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 300-312.	22.6	128
61	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. <i>World Neurosurgery</i> , 2019, 127, 695-709.	1.5	22
62	Acromegaly and Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 399-408.	2.2	46
63	Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. <i>Scientific Reports</i> , 2019, 9, .	3.5	26
64	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 855-865.	22.6	91
65	Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico's Andrologo survey. <i>Andrology</i> , 2019, 7, 769-777.	3.3	45
66	Acromegaly. <i>Nature Reviews Disease Primers</i> , 2019, 5, .	50.7	350
67	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on a real-world evidence. <i>Endocrine</i> , 2019, 64, 657-672.	2.6	41
68	Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study. <i>Pituitary</i> , 2019, 23, 203-211.	2.8	24
69	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 21, 57-65.	7.1	31
70	OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.3	3
71	SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.3	7
72	SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM). <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.3	1

#	ARTICLE	IF	PR CITATIONS
73	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018, 61, 118-124.	2.6	22
74	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 17-26.	22.6	152
75	Air pollution and female fertility: a systematic review of literature. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, .	4.3	166
76	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. <i>Endocrine</i> , 2018, 62, 663-680.	2.6	13
77	Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial. <i>Frontiers in Endocrinology</i> , 2018, 9, .	4.1	27
78	Smoke, alcohol and drug addiction and male fertility. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, .	4.3	227
79	Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, , jc.2016-2555.	4.2	29
80	Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 273-283.	7.1	119
81	Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. <i>Pituitary</i> , 2017, 20, 46-62.	2.8	197
82	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	3.0	70
83	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , 2017, 158, 1527-1532.	2.6	17
84	Cardiovascular alterations in adult GH deficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 25-34.	5.4	35
85	The environment and male reproduction: The effect of cadmium exposure on reproductive function and its implication in fertility. <i>Reproductive Toxicology</i> , 2017, 73, 105-127.	2.8	241
86	The role of vitamin D in male fertility: A focus on the testis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 285-305.	7.1	97
87	Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. <i>Endocrine</i> , 2017, 60, 65-72.	2.6	7
88	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0186508.	2.4	41
89	Influence of Bisphenol A on Type 2 Diabetes Mellitus. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 989.	3.1	80
90	Investigation of sperm telomere length as a potential marker of paternal genome integrity and semen quality. <i>Reproductive BioMedicine Online</i> , 2016, 33, 404-411.	2.8	76

#	ARTICLE	IF	PR CITATIONS
91	Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study. <i>Endocrine</i> , 2016, 54, 516-523.	2.6	30
92	Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 611-629.	22.6	533
93	The effect of FT500 Plus \hat{A} on ovarian stimulation in PCOS women. <i>Reproductive Toxicology</i> , 2016, 59, 40-44.	2.8	28
94	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. <i>Bone</i> , 2016, 86, 79-85.	3.6	30
95	The safety of treatments for prolactinomas. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 503-512.	2.7	21
96	The degree of urinary hypercortisolism is not correlated with the severity of Cushing's syndrome. <i>Endocrine</i> , 2016, 55, 564-572.	2.6	39
97	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine</i> , 2016, 55, 872-884.	2.6	50
98	Cushing's disease: the burden of illness. <i>Endocrine</i> , 2016, 56, 10-18.	2.6	159
99	Association between vitamin D and sperm parameters: Clinical evidence. <i>Endocrine</i> , 2016, 58, 194-198.	2.6	38
100	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , 2016, 57, 539-543.	2.6	10
101	Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. <i>Endocrine</i> , 2016, 56, 603-620.	2.6	16
102	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. <i>Endocrine</i> , 2016, 57, 314-325.	2.6	22
103	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 9718-9731.	1.7	22
104	Erectile Dysfunction Is Common among Men with Acromegaly and Is Associated with Morbidities Related to the Disease. <i>Journal of Sexual Medicine</i> , 2015, 12, 1184-1193.	0.5	30
105	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, .	3.2	28
106	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015, 9, .	2.8	157
107	The Treatment of Cushing's Disease. <i>Endocrine Reviews</i> , 2015, 36, 385-486.	25.8	426
108	Adverse events associated with somatostatin analogs in acromegaly. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1213-1226.	2.7	47

#	ARTICLE	IF	PR CITATIONS
109	The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. <i>Endocrine</i> , 2015, 50, 725-740.	2.6	45
110	Osilodrostat, a potent oral 11 β -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. <i>Pituitary</i> , 2015, 19, 138-148.	2.8	149
111	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine Abstracts</i> , 2015, , .	0.0	2
112	Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. <i>Journal of Endocrinological Investigation</i> , 2014, 22, 860-865.	3.0	27
113	Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. <i>Journal of Endocrinological Investigation</i> , 2014, 25, 932-937.	3.0	5
114	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2014, 30, 497-506.	3.0	16
115	Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2014, 32, 390-394.	3.0	23
116	The treatment with growth hormone receptor antagonist in acromegaly: Effect on vascular structure and function in patients resistant to somatostatin analogues. <i>Journal of Endocrinological Investigation</i> , 2014, 33, 663-670.	3.0	37
117	Growth hormone, prolactin, and sexuality. <i>Journal of Endocrinological Investigation</i> , 2014, 35, 782-794.	3.0	71
118	Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 1017-1030.	3.0	48
119	Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 99-112.	3.0	38
120	LCI699, a Potent 11 β -hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1375-1383.	4.2	183
121	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. <i>Gene</i> , 2014, 534, 282-285.	2.4	27
122	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. <i>Clinical Endocrinology</i> , 2014, 81, 408-417.	2.5	113
123	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. <i>Pituitary</i> , 2014, 18, 604-612.	2.8	59
124	Investigational therapies for acromegaly. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 955-963.	4.0	14
125	Preoperative workup in the assessment of adrenal incidentalomas: outcome from 282 consecutive laparoscopic adrenalectomies. <i>BMC Surgery</i> , 2013, 13, .	1.6	28
126	The Metabolic Profile in Active Acromegaly is Gender-Specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E51-E59.	4.2	62

#	ARTICLE	IF	PR CITATIONS
127	Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 372-379.	4.2	98
128	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2013, 46, 181-198.	2.6	29
129	Identification of vitamin D (VDR) and retinoic X (RXR) receptor in normal and neoplastic human reproductive tissues. <i>Endocrine Abstracts</i> , 2013, , .	0.0	2
130	Cardiac Abnormalities in Acromegaly. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2012, 3, 309-318.	0.9	28
131	Subclinical Cushing's syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 497-505.	5.4	58
132	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. <i>Clinical Endocrinology</i> , 2012, 76, 264-271.	2.5	68
133	Resistance to Somatostatin Analogs in Acromegaly. <i>Endocrine Reviews</i> , 2011, 32, 247-271.	25.8	241
134	Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. <i>Pituitary</i> , 2011, 15, 539-551.	2.8	38
135	Medical Treatment of Cushing's Disease with Pasireotide. <i>European Endocrinology</i> , 2010, 8, 99.	2.6	5
136	Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2907-2914.	4.2	59
137	Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 528-537.	4.2	57
138	Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3746-3756.	4.2	144
139	Significant tumour shrinkage after 12 months of lanreotide Autogel 120 mg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009, 71, 237-245.	2.5	68
140	The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 223-230.	4.2	320
141	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1331-1331.	4.6	0
142	Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 135-149.	3.7	186
143	Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2639-2646.	4.2	85
144	Correlation of in Vitro and in Vivo Somatotrophic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1412-1417.	4.2	119

#	ARTICLE	IF	PR CITATIONS
145	Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 65-69.	4.2	67
146	Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 476-482.	4.2	85
147	Cushing's syndrome: aftermath of the cure. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1381-1391.	1.6	83
148	Bone Demineralization and Vertebral Fractures in Endogenous Cortisol Excess: Role of Disease Etiology and Gonadal Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1779-1784.	4.2	143
149	Sulfur Amino Acids in Cushing's Disease: Insight in Homocysteine and Taurine Levels in Patients with Active and Cured Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6616-6622.	4.2	34
150	The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 327-339.	3.7	157
151	Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4493-4502.	4.2	74
152	Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2452-2462.	4.2	255
153	Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1674-1683.	4.2	124
154	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , 2003, 58, 169-176.	2.5	104
155	Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. <i>Clinical Endocrinology</i> , 2003, 58, 302-308.	2.5	110
156	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3196-3201.	4.2	127
157	Nephrolithiasis in Cushing's Disease: Prevalence, Etiopathogenesis, and Modification after Disease Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2076-2080.	4.2	98
158	Central Diabetes Insipidus and Autoimmunity: Relationship between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients with Central Diabetes Insipidus of Known and Unknown Etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1629-1636.	4.2	117
159	Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients with Cushing's Disease during Active Disease and 1 Year after Disease Remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2527-2533.	4.2	343
160	Short-Term Suppression of GH and IGF-I Levels Improves Gonadal Function and Sperm Parameters in Men with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4193-4197.	4.2	41
161	Early Vascular Alterations in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3174-3179.	4.2	101
162	The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1088-1093.	4.2	102

#	ARTICLE	IF	PR CITATIONS
163	Cardiovascular Consequences of Early-Onset Growth Hormone Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3097-3104.	4.2	87
164	Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. <i>Clinical Endocrinology</i> , 2002, 56, 153-158.	2.5	72
165	Early Vascular Alterations in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3174-3179.	4.2	20
166	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , 2001, 54, 97-106.	2.5	8
167	Increased arterial intima-media thickness by B-mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001, 54, 515-524.	2.5	104
168	Reply. <i>Clinical Endocrinology</i> , 2001, 54, 411-412.	2.5	0
169	Title is missing!. <i>Pituitary</i> , 2001, 4, 251-257.	2.8	27
170	Title is missing!. <i>Pituitary</i> , 2001, 4, 153-161.	2.8	36
171	Title is missing!. <i>Pituitary</i> , 2001, 4, 187-193.	2.8	1
172	Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5256-5261.	4.2	216
173	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1551-1557.	4.2	103
174	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clinical Endocrinology</i> , 2000, 52, 319-327.	2.5	96
175	Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. <i>Clinical Endocrinology</i> , 2000, 52, 447-455.	2.5	40
176	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. <i>Clinical Endocrinology</i> , 2000, 53, 53-60.	2.5	82
177	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000, 53, 13-19.	2.5	57
178	Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2247-2252.	4.2	179
179	Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1919-1924.	4.2	166
180	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2664-2672.	4.2	356

#	ARTICLE	IF	PR CITATIONS
181	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2349-2352.	4.2	18
182	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1277-1282.	4.2	95
183	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1986-1991.	4.2	72
184	Title is missing!. Pituitary, 1999, 1, 115-120.	2.8	83
185	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1277-1282.	4.2	31
186	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1986-1991.	4.2	23
187	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2349-2352.	4.2	5
188	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. Clinical Endocrinology, 1998, 49, 77-84.	2.5	13
189	Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clinical Endocrinology, 1998, 48, 655-662.	2.5	86
190	Impairment of Bone Status in Patients with Central Diabetes Insipidus*. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2275-2280.	4.2	24
191	Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 807-813.	4.2	39
192	Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3574-3579.	4.2	155